Compare LQDA & SEZL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LQDA | SEZL |
|---|---|---|
| Founded | 2004 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Diversified Financial Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.2B |
| IPO Year | 2018 | N/A |
| Metric | LQDA | SEZL |
|---|---|---|
| Price | $35.17 | $72.29 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 10 | 4 |
| Target Price | $37.40 | ★ $113.75 |
| AVG Volume (30 Days) | ★ 1.7M | 966.4K |
| Earning Date | 11-03-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 104.61 |
| EPS | N/A | ★ 3.24 |
| Revenue | $69,216,000.00 | ★ $418,632,890.00 |
| Revenue This Year | $904.79 | $68.97 |
| Revenue Next Year | $188.25 | $26.02 |
| P/E Ratio | ★ N/A | $21.70 |
| Revenue Growth | ★ 343.41 | 88.74 |
| 52 Week Low | $10.37 | $24.86 |
| 52 Week High | $35.54 | $186.74 |
| Indicator | LQDA | SEZL |
|---|---|---|
| Relative Strength Index (RSI) | 67.11 | 60.34 |
| Support Level | $32.11 | $66.07 |
| Resistance Level | $35.54 | $76.39 |
| Average True Range (ATR) | 1.50 | 4.42 |
| MACD | -0.05 | 1.51 |
| Stochastic Oscillator | 92.26 | 78.99 |
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.
Sezzle Inc is a financing institution that offers technology-driven payment platform. It allows customers to split their purchase into four installments and pay over 6 weeks with only the first payment due at the time of purchase. Companies operations comprise one reportable segment, the majority of which derives revenue from payment processing platform in North America.